Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous natural progesterone for luteal phase deficiency
2016-002731-14Phase 3Terminated
- Sponsor
- IBSA Group
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in luteal insufficiency comparing Progesterone 25 mg subcutaneous daily with Placebo (2 arms). Primary endpoint: Ongoing pregnancy rate. Started Feb 2018; status: terminated.
02
Drugs
progesterone
03
Conditions
luteal insufficiency
Beyond the preview
Go deeper on 2016-002731-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002731-14.